Author's response to reviews

Title: Actos Now for the Prevention of Diabetes (ACT NOW) Study

Authors:

Ralph A. DeFronzo (albarado@uthscsa.edu)
MaryAnn Banerji (MaryAnn.Banerji@downstate.edu)
Thomas A. Buchanan (buchanan@usc.edu)
Stephen C. Clement (clements@gunet.georgetown.edu)
Robert R. Henry (rrhenry@vapop.ucsd.edu)
Abbas E. Kitabchi (akitabchi@utmem.edu)
Sunder Mudaliar (mudaliar@adamember.org)
Nicolas Musi (musi@uthscsa.edu)
Robert E. Ratner (ratnermri@aol.com)
Peter Reaven (peter.reaven@med.va.gov)
Dawn Schwenke (Dawn.Schwenke@med.va.gov)
Frankie B. Stentz (fstentz@utmem.edu)
Devjit Tripathy (tripathy@uthscsa.edu)

Version: 4  Date: 20 May 2009

Author’s response to reviews:

Date: May 19, 2009
To: BioMed Central Editorial
From: Ralph A. DeFronzo, MD
RE: Manuscript #1207179308236082

We are returning our manuscript #1207179308236092 titled “Actos Now for the Prevention of Diabetes (ACT NOW) Study” for consideration for publication in BioMed Central Editorial.

We thank the reviewer for his/her helpful comments. Below we have listed a detailed response to each of the queries. We also have addressed the issue raised by the Editor.

1. “of FPG” deleted
2. “from” deleted
3. CBC spelled out
4. We have clarified the sentence. The maximum dose of pioglitazone was 45 mg/day
5. Corrected to (42)
6. We stated that the exclusion criteria are listed in Table 1

We also have addressed the editor’s comments as follows:
1. A Conflict of Interest Statement has been added.
2. An Author’s Contribution section has been added
3. The abstract has been restructured as requested.